Biotechnology

Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives

August 23, 2021 8:00 AM

SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2021 / Oncology Pharma, Inc. (OTC PINK:ONPH) defines its objective and strategy for recently signed Co-Development deal. The primary goal of the Co-Development plan is to bring new pharmaceutical drug formulations to market with a focused approach that aims to reduce overall costs and time to commercialization. Oncology Pharma is focusing on rare pediatric cancers. Pediatric cancers are traditionally...

Read more

Dr. Southey and Dr. Zarrebini Join M2Bio Sciences and Establish M2Bio Blockchain Research and Technology Group

August 19, 2021 10:30 AM

CAPE TOWN, SA / ACCESSWIRE / August 19, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update: WUHAN GENERAL GROUP, in partnership with Catena. MBA, has formed the M2Bio Blockchain Research and Technology Group. The company is committed to its long-term vision and mission to improve...

Read more

Pressure BioSciences, Inc. Reports Strong Second Quarter 2021 Financial Results

August 19, 2021 9:45 AM

Significant Growth Reported in Total Revenue (127%), Instrument Sales (178%), and BaroFold/UST Services (298%); Significant Decrease in Operating Loss (51%) Achieved Investor Call Scheduled for Thursday, August 19, 2021 at 4:30 p.m. EDT SOUTH EASTON, MA / ACCESSWIRE / August 19, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments,...

Read more

Helix BioPharma Corp. Announces Appointment of New Director

August 19, 2021 8:00 AM

RICHMOND HILL, ON / ACCESSWIRE / August 19, 2021 / Helix BioPharma Corp. (TSX:HBP) ('Helix' or the 'Company'), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Dr. Krzysztof Saczek has been appointed as a member of the Board of Directors of the Company effective immediately. Dr. Saczek is a Paediatric Surgeon, experienced in treating solid tumors, including...

Read more

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

August 19, 2021 8:00 AM

Two-year VenoValve® data shows average improvements in reflux, disease manifestations and pain, of 63%, 60%, and 93%, respectively Patients with venous ulcers who experienced dramatic ulcer healing had no venous ulcer recurrences No safety issues occurred during the one-year reporting period following the study completion IRVINE, CA / ACCESSWIRE / August 19, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the...

Read more

Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.

August 19, 2021 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) With much anticipation, Oncology Pharma, Inc. has finalized a Co-Development Agreement with NanoSmart Pharmaceuticals, Inc. Oncology Pharma will pursue the early feasibility and nonclinical development of a dactinomycin nanoemulsion drug product intended for the treatment of pediatric cancer. Oncology Pharma is pleased to be moving forward with the...

Read more

Phyto Extractions' Shatter Run Visits 420th Retailer on Final Leg of Cross-Country Sales Tour

August 18, 2021 4:15 PM

LANGLEY, BC / ACCESSWIRE / August 18, 2021 / Phyto Extractions Inc. (formerly, Adastra Labs Holdings Ltd.) (CSE:XTRX)(FSE:D2EP) ("Phyto Extractions™", "Phyto" or the "Company") strives to continuously bring consumers new and innovative products to enhance their experience and overall enjoyment. Phyto Extractions™ 'is known for its iconic concentrate products and brand success, built during the legacy market era. Shatter is Phyto's newest product...

Read more

Pressure BioSciences to Host Q2 2021 Financial Results and Business Update on Thursday, August 19, 2021

August 18, 2021 10:05 AM

Company to Discuss Strong Q2 2021 Financial Results, Give Update on Current Activities, and Take Questions on Aggressive Growth Plan Laid Out for the Company on August 5, 2021 SOUTH EASTON, MA / ACCESSWIRE / August 18, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Second Quarter 2021 financial results and provide a business update. Anyone...

Read more

Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering

August 17, 2021 5:45 PM

SAN DIEGO, CA / ACCESSWIRE / August 17, 2021 / Dermata Therapeutics, Inc. ("Dermata" or the "Company") (NASDAQ:DRMA, DRMAW), a clinical-stage medical dermatology company focused on identifying, developing and commercializing innovative pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases and conditions, today announced the closing of its previously announced initial public offering of 2,571,428 shares of its...

Read more

Pressure BioSciences to Expand on Recent Announcement of Over $1,000,000 in Orders Received by its New Eco-Friendly Agrochem Subsidiary in First Month of Operations

August 17, 2021 10:45 AM

Company Invites Investors, Analysts, and Advisors to Attend Its Real-Time, Interactive PBI Agrochem Update, Followed by a Q&A Session, on Wednesday, August 18, 2021 SOUTH EASTON, MA / ACCESSWIRE / August 17, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and services to the worldwide life sciences,...

Read more

Woodward Pharma Services LLC Acquires LOVAZA(R) Capsules

August 17, 2021 10:30 AM

WIXOM, MI / ACCESSWIRE / August 17, 2021 / Woodward Pharma Services LLC ("Woodward"), a Michigan-based specialty pharmaceutical company focused on acquiring, licensing and commercializing branded and generic products for the U.S. market, announces the acquisition of LOVAZA® (LO-VEY-ZA) soft gelatin capsules. LOVAZA® (omega-3-acid ethyl esters) capsules are indicated as an adjunct to diet to reduce triglyceride levels in adult patients with...

Read more

Thermic Science Files 2021 Second Quarter Financials Ending June 30, 2021, Continuing to Bring the Company in Compliance with the OTC Market to Pink Current Status and No Shell Designation by Filing its Financials & Business Activities Reporting Requirements

August 17, 2021 10:10 AM

NASHVILLE, TN / ACCESSWIRE / August 17, 2021 / Thermic Science International Corporation, formerly known as Omnicanna Health Solutions, Inc. aka Endocan Corporation. (WKN:A1W61J) (ISIN:US29271J1097) (OTC:ENDO), is pleased to announce the unaudited interim consolidated financial results of the Company for the second quarter ended June 30, 2021. The full version of the financial statements and the management discussion and analysis can be viewed...

Read more

Applied UV Reports Second Quarter 2021 Results

August 17, 2021 7:00 AM

Accelerated global commercial strategy for infection control products via partnerships and distribution Airocide® air purifications installations in hospitals, museums, wineries, and school systems Independent lab results confirmed SteriLumen's Lumicide™Ribbon kills SARS-CoV-2 (COVID-19 Virus) Hotel & hospitality demand for MunnWorks subsidiary recovering Continued focus on inorganic growth strategy via synergistic acquisitions Strengthened...

Read more

Wuhan General Group Launches M2Bio Labs in Hout Bay, South Africa

August 16, 2021 9:15 AM

CAPE TOWN, SA / ACCESSWIRE / August 16, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research, is pleased to announce the following corporate update: M2Bio Sciences launches M2Bio Labs alongside the distinguished Bay Harbour Market in Hout Bay. This picturesque setting encompasses 7500 square feet which will house the...

Read more

Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

August 13, 2021 8:05 AM

Continued execution on XCART TM pre-clinical development plan and progress toward IND-enabling studies  Strong royalty growth with PolyXen® platform technology  Bolstered cash position with recently completed $12.5 million private placement  FRAMINGHAM, MA / ACCESSWIRE / August 13, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform...

Read more

Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results

August 13, 2021 7:50 AM

TORONTO, ON / ACCESSWIRE / August 13, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and nine months ended June 30, 2021 and provided an update on its business. During the quarter, the company achieved key interim milestones for both of its lead product candidates, EB05 and EB01. Independent monitoring boards...

Read more

Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

August 12, 2021 4:00 PM

Executed binding term sheet with Sorrento Therapeutics (Nasdaq:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadic's lead COVID-19 vaccine candidate New collaboration with India's Syngene International to develop a COVID-19 vaccine candidate New co-development collaboration with South...

Read more

Applied UV Continues Successful Installation of Airocide(R) Systems at U.S. Army's Aberdeen Proving Ground

August 12, 2021 9:25 AM

Since 2020, over 100 Airocide® units installed to help critical U.S military facility remain open and protect staff and visitors MOUNT VERNON, NY / ACCESSWIRE / August 12, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens...

Read more

EV Biologics Briefs Shareholders on Market Cap Peer Comparison

August 12, 2021 9:00 AM

NASHVILLE, TN / ACCESSWIRE / August 12, 2021 / EV Biologics Corp, OTC Pink:YECO, today briefed shareholders on its current value compared to other public biotechnology companies in its peer group. Please view the chart at: https://www.evbiologics.com/marketcap/. CEO Daniel Mckinney commented: 'Our market cap is less than half that of our closest listed peer. Our goal is to continue to build value and become the largest listed company by market...

Read more

Pressure BioSciences New Eco-Friendly Agrochem Subsidiary Receives Over $1,000,000 in Orders in First Month of Operations

August 12, 2021 8:31 AM

PBI Agrochem Integration into the Sales Channels of Its Planned Asset Acquisition of a Global, Environmentally Responsible Agrochem Company is Expected to Result in a Significant Q3 2021 Impact SOUTH EASTON, MA / ACCESSWIRE / August 12, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the...

Read more